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A mathematical model of microbial folate biosynthesis and 
utilisation: implications for antifolate development
J. Enrique Salcedo-Sora and Mark T. Mc Auley 
The metabolic biochemistry of folate biosynthesis and utilisation has evolved into a complex
network of reactions. Although this complexity represents challenges to the field of folate
research it has also provided a renewed source for antimetabolite targets. A range of improved
folate chemotherapy continues to be developed and applied particularly to cancer and chronic
inflammatory diseases. However, new or better antifolates against infectious diseases remain
much  more  elusive.  In  this  paper  we  describe  the  assembly  of  a  generic  deterministic
mathematical  model  of  microbial  folate  metabolism.  Our  aim  is  to  explore  how  a
mathematical model could be used to explore the dynamics of this inherently complex set of
biochemical reactions. Using the model it was found that: (1) a particular small set of folate
intermediates are overrepresented, (2) inhibitory profiles can be quantified by the level of key
folate products, (3) using the model to scan for the most effective combinatorial inhibitions of
folate enzymes we identified specific targets which could complement current antifolates, and
(4)  the  model  substantiates  the  case  for  a  substrate  cycle  in  the  folinic  acid biosynthesis
reaction. Our model is coded in the systems biology markup language and has been deposited
in the BioModels Database (MODEL1511020000), this makes it accessible to the community
as a whole.
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1 Introduction
Infectious diseases are still a major burden to human health and economic development. For
example, in 2013 mortality due to tuberculosis 2013 was estimated at 1.4 million people.1
Moreover, Malaria causes an astonishing 200 to 500 million of clinical episodes a year2–4
with nearly 600 thousand deaths in 2013.4 Folate metabolism is a proven drug target with
significant clinical efficacy and antifolates have been deployed for the treatment of a wide
range of infectious diseases.5 However, due to increasing drug resistance their efficacy has
been compromised forcing in some cases the withdrawal of formulations of antifolates unless
they are combined with a further antimicrobial that works through a different mechanism of
action.6  Furthermore,  the  available  antibiotics  are  not  extensive  nor  comprehensive.  For
instance,  antimicrobials  against  Gram-negative bacteria  are  limited and the drugs to  treat
morbid parasitic  infections  are  scarce  and their  treatment  is  clinically  unsafe.7 Since  the
production of new antibiotics is lengthy and costly, it is imperative that there is a continued
effort to identify pharmacological approaches to extend the life of this well known source of
antimicrobial  targets  and  counteract  the  detrimental  consequences  of  antifolate  drug
resistance. Due to the knowledge accumulated over eight decades on folate metabolism and
the evidence on the efficacy of antifolates at killing sensitive cells, the folate biosynthesis and
usage pathways continue to  be a worthwhile avenue for antimicrobial  developmental  and
repurposing.8 Nonetheless,  in  order  to  identify key biochemical  targets  it  is  necessary to
appreciate  fully  the  dynamics  of  folate  in  microbial  metabolism  and  cell  growth.
Fundamentally, cell proliferation requires folate for the biosynthesis of nucleic acids and the
metabolism  of  amino  acids.  Animals  can  derive  sufficient  folate  from  their  diet  or  by
symbiotic  relationships  in  their  intestinal  microflora.  Thus,  they  have  disposed  of  the
endogenous  folate  biosynthesis  pathway.9,10  However,  unlike  animals,  most  free  living
microorganisms (and plants) are capable of either salvaging folate from their environment, or
producing  de novo  folate  when there  is  a  decline  in  folate  availability.  Therefore,  if  the
immediate environment and diet do not offer this essential vitamin the biosynthetic pathway
of folate becomes key for the viability of active proliferatingmicroorganisms.11 Crucially,
this biochemical switch characterises the behaviour of most microbial pathogens  including
bacteria12 and parasitic single-cell eukaryotes such as the malaria parasites.8 To combat these
pathogens antifolates of clinical use in medical and veterinary practice target primarily the
following three enzymes: dihydropteroate synthase (DHPS), dihydrofolate reductase (DHFR)
or thymidylate synthase (TS), while an enzyme of the Shikimate pathway is the target of the
herbicidal glyphosate. Thus, the pharmacological utility of the extensive range of other 
enzymes involved in the folate biosynthesis and utilisation network are still to be fully 
exploited.
Mainly due to the association its dysregulation has with cancer folate metabolism has been
more intensively studied in mammals. This experimental work has been used to inform the
assembly  of  a  number  of  mathematical  models  of  folate  metabolism.13–19  In  silico
mammalian models have been used to represent in vivo purine biosynthesis,20 the kinetics of
the folate cycle in human breast carcinoma cells,21 the impact of vitamin B12 deficiency on
the  folate  cycle,13  the  influence  of  genetic  polymorphisms in  methylene  tetrahydrofolate
reductase and thymidylate synthesis,22 the effect of epithelial folate concentrations on DNA
methylation rate and purine and thymidylate synthesis,23 the high correlation between tissue
and plasma folate and the low correlation between liver and plasma folate,16 and how vitamin
B-6 restriction alters one-carbon metabolism in cultured HepG2 cells.19 These mathematical
models have all worthwhile features and have deepened our understanding of the complex
dynamics  which  underpins  the  folate  cycle  in  mammals.  However,  to  our  knowledge  at
present,  there  is  no  mathematical  model  which  has  represented  microbial  de  novo
biosynthesis as well as the usage of folate (the folate cycle). Thus, it could be argued that the
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microbial  biochemical  folate  system  remains  less  well  understood  than  its  mammalian
counterpart.
In this paper we describe the assembly of a mathematical model of the microbial biosynthetic
and usage pathways. This model is based on the biochemical architecture of a single celled
microorganism, and is underpinned by known enzyme kinetics. The robustness of our model
is based on its capacity to represent known folate inhibitory profiles as well as its capacity to
predict  effective new drug combinatorial  profiles.  Furthermore,  this  model  includes folate
metabolites recently identified as being involved in dormancy related persister bacteria and
illustrates the likely metabolic folate profile of such a phenotype. Together these features of
the emodel suggest that our model is a suitable template which could help to exploit novel
aspects of this complex network for new antifolate chemotherapy.
2 Methods
The model proposed here comprises 31 reactions and 51 metabolites. The different reactions
are in Table 1 with extended annotation in Table S1 with the metabolites abbreviated as in
Table S2 (ESI†). The components of our model are informed by the existing kinetic models
briefly described above, and by the most recent reviews of microbial folate metabolism.8,24
Moreover,a  number  of  microbial  metabolic  representations  that  describe  folate  related
reactions were explored.  These pathways are archived within the KEGG database (Kyoto
encyclopedia  of  genes  and genomes  http://www.genome.jp/kegg/)  (accessed  July 2015)25
which  is  based  on  the  comparative  genomics  from  the  hundredsof  microbial  genomes
sequenced to date.26 Kinetic parameters were compiled from the  enzyme database BRENDA
(accessed July 2015)27 (Tables S3 and S4, ESI†). Kinetic parameters for ADCS (reaction
(8)), for E. coli, were extrapolated from ref. 28. Kinetic parameters for ADCL (reaction (9)),
for  P.  falciparum,  were  extrapolated  from  ref.  29.  The  final  curated  model  consists  of
reactions reported from all three microbial models  E. coli,  S. cerevisiae, and  P. falciparum
and encompasses a biosynthesis component (the Shikimate pathway leading to the synthesis
of pABA fromglycolytic intermediates, the pteridin biosynthesis pathway from GTP, and the
reactions  leading  to  the  production  of  fully  reduced  and  polyglutamated  folate),  and  an
interconversion cycle of reduced andpolyglutamated folate products (Fig. 1). All reactions are
listed in Table S1 and all metabolites and their abbreviations are listed in Table S2 (ESI†). 
The vectorial assembly of this model was created with systems biology graphical notation
(SBGN) (http://www.sbgn.org/Main_Page)30 and implemented in VANTED (Version 2.2.1,
http://vanted.ipkgatersleben.de/).31 We then converted this biochemical network into a series
of  reactions  (Table 1 and Table  S1,  ESI†) and asembled them in Version 4.14.89 of the
modelling and simulation software tool  Copasi.32 The initial  velocity of  each reaction is
underpinned by  a  rate  law that  depends  on  the  concentrations  of  the  reaction  substrates,
products,  and  co-factors.  These  rate  laws  are  nonlinear  and  in  general  are  described  by
Michaelis–Menten kinetics (list  of ODEs in ESI†) for either one,  two, or  three substrates
assuming  a  random-order  mechanism.33  The  following  mathematical  expressions
exemplified  the  different  Michaelis–Menten  equations  as  used  for  this  model  for  one
substrate, two substrates, and three substrates:33
The equations for reactions that had metabolite modifiers (inhibitors) included (see Table 1)
are exemplified by eqn (4) where the concentration of the inhibitory metabolite is taken
into account, together with its affinity constant (Ki), by its effect on the  Km values in the
denominator.  Dihydrofolate  (DHF)  has  been  shown  to  act  as  inhibitor  of  a  number  of
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reactions in the folate cycle. Chiefly among them is folylpolyglutamate synthase (reaction
(16)) which DHF inhibits with a constant of 3.1 mM.34 The model built here includes DHF
as a modifier (inhibitor) of reactions (16), (19), (21) and (22). THF has also been involved in
regulatory feedback by inhibiting reactions (10) and (17).8 This is reflected here by including
THF as a modifier in such reactions (list  of ODEs in ESI†). The model does not include
membrane  transport  of  folates.  Folate  membrane  transporters  have  been  found  in  folate
heterotrophs24  and  organisms  with  dual  de  novo  folate  biosynthesis  and  salvage
capabilities.35–37 The former are obviously not covered by the model assembled here. Some
single-celled eukaryotes (i.e. Apicomplexan such as malaria and toxoplasmosis parasites)
37 and plants can perform both biosynthesis as well as salvage of folate from environment
mainly via the FBT family of transporters.38 This extra layer of complexity is not included in
our model.
Substrate steady state concentrations available mainly from ref. 39 were included as initial
concentrations. The initial concentration of boundary metabolites was fixed. These included
PEP, EP, and GTP. These are the substrates for the initial reactions of the Shikimate pathway
and  the  pterin  biosynthesis,  respectively.  Also  fixed  were  the  initial  concentrations  of
cofactors for which recycling reactions are not part of the system: ATP, NADH, NADPH,
Gln, Gly, Ser and Lp. The reactions that generate the products using folates as cofactors in
anabolic reactions (i.e. Met, dTMP and formyl-mtRNA) needed to have their substrates (Hcy,
dUMP, and mtRNA) also fixed (Table S5, ESI†). Additionally, it was also considered that the
average microorganism would have its folate pool most polyglutamated. For example, E. coli
has  approximately  50%  of  folates  polyglutamated  and  S.  cerevisiae  nearly  fully
polyglutamated.12,40  To  reflect  this,  all  folate  intermediates  containing  fully  reduced
tetrahydrofolate (THF) in this model are denoted as polyglutamated by using the suffix Glu in
their abbreviations. The maximal rates (Vmax in micromoles (Litre)_1 (min)_1) of enzymatic
reactions were calculated from the specific activities41 of purified protein extracts as reported
in BRENDA (micromoles (mg of protein)_1 (min)_1).27 In a bacterial cell such as E. coli
proteins constitute about 55% of the dry cell weight and the cytoplasm has a density of 1.1
with 70% water.41 With these parameters the Vmax values were calculated by converting
the mass (mg of protein) of the specific activity of a given enzyme to volume in litres to
represent Vmax values41 as explained in Table S4 (ESI†). The model is encoded in the
systems biology markup language (SBML)42 and was submitted to the BioModels Database,
a repository for computational models of biological processes.43 This means that the model
is accessible and can be updated as the biological knowledge of the system advances.
3 Results
3.1 Initial examination of the model
Once the initial set of parameters were added to the model we ran a number of simulations. It
was found that the system reached steady state at approximately 300 minutes (Fig. 2 and Fig.
S1 and Table S5, ESI†). Fig. 2 captures the steady state values for the folate cycle. Fig. 2A
represents the intermediates of the cycle, while Fig. 2B represents the products of the cycle,
namely  methionine,  dTMP  and  formyl-met-tRNA  (fmtRNA).  The  concentrations  of  the
metabolites and the fluxes related to the biosynthesis of folates range over several orders of
magnitude as summarized in Table S5 (ESI†). Importantly, the folate pool seems to be stored
mainly as two intermediates:  the polyglutamated and fully  reduced form THFGlu and its
intermediate carrying the one-carbon unit as methenyl (meTHFGlu) (Fig. 2A and Table 2). 
This is an important finding of the model since neither THFGlu nor meTHFGlu are direct
cofactors  for  the  anabolic  reactions  where  folates  are  involved.  On  the  other  hand,  the
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products derived directly from the folate cycle reactions are represented by methionine at a
concentration of 172 mMand dTMP at a concentration of 45.7 mM. Themodified methionyl-
transfer RNA (fmtRNA) reaches a steady state at a much lower level (2.15  mM) than the
other  products  (Fig.  2B).  From  these  the  only  metabolite  with  a  reported  steady  state
concentration in microorganisms is methionine at a mean value of 142 mM39 which is close
to the value derived from the simulation of this model (172 mM).
3.2 Modelling the effect of known antifolates
We modelled the effect of inhibiting enzymes by running parameter scans of the Vmax of a
given enzyme from the initial Vmax value entered for that enzyme down to decimal minimal
values approaching zero (0.01 micromoles (Litre)_1 (min)_1) to simulate maximal inhibition
(Fig. 3). The most commonly targeted enzyme by antifolates of clinical use is DHFR. Seven
folate  intermediates  (THF,  THFGlu,  myTHFGlu,  meTHFGlu,  fTHFGlu,  ffTHFGlu  and
MTHFGlu)  and  the  three  products  (Met,  dTMP and  fmtRNA)  were  all  affected  by  the
reduction of the  Vmax of DHFR (Fig. 3). The effect on metabolites present at much lower
levels  such  as  fTHFGlu  and  fmtRNA  is  less  visible.  Importantly,  the  metabolite
concentrations were at their lowest from the point where approximately a reduction of 90% of
the Vmax had been reached. The methyl carrier MTHFGlu, and both products methionine and
dTMP are  at  4% and 10%, respectively,  of  their  initial  steady state  concentrations  when
DHFR was inhibited.  The inhibition of DHPS,  another commonly targeted folate enzyme
(currently by using sulfa drugs), affects the levels of THF and myTHFGlu, the two immediate
products of de novo folate biosynthesis and one-carbon folate metabolism, respectively (Fig.
S2,  ESI†).  Similarly,  the  effects  of  targeting  the  Shikimate  pathway,  simulated  here  by
inhibiting  PSCVT  (phosphoenolpyruvate:  3-phosphoshikimate  5-O-(1-carboxyvinyl)-
transferase), target of glyphosate, presented a similar inhibition profile to that observed for
DHPS.  The  inhibition  ofTS  on  the  other  hand,  was  limited  to  the  decline  of  dTMP  to
negligible levels (Fig. S2, ESI†).
3.3 Modelling the effect of known antifolate combination therapies
Antifolate chemotherapy has been deployed using inhibitors that target at least two enzymes
of folate biosynthesis and usage pathways and usually work due to a synergistic effect.44 The
most  common of  such  combinations  is  a  DHFR inhibitor  and  a  DHPS  inhibitor  for  the
treatment of infectious diseases. Targeting DHFR and TS has also been used to kill cancerous
cells.45 The effects of the combined reduction of the  Vmax for DHFR and DHPS (Fig. 4),
and DHFR and TS (Fig. S3, ESI†) were simulated. The response of the two folate products
(Met and dTMP) and the two metabolic intermediates (THFGlu and meTHFGlu) were used to
illustrate the effects of these combined inhibitions. The inhibition of DHFR and DHPS has an
overall effect on all of these metabolites while the inhibition of DHFR and TS has its main
effect on dTMP, which was significantly reduced (Fig. S3, ESI†). An important aim of this
model was to find new potential inhibitory combinations that could reduce the levels of folate
metabolites and products which could work more effectively than the current antifolates. As
the  model  successfully  simulated  the  known  effects  of  inhibiting  DHFR46  (Fig.  3),  we
therefore decided that it would be logical to investigate the effects of inhibiting DHFR and a
second target. Using the levels of dTMP as an indicator of cell survival, a scan of the Vmax of
DHFR was performed while the Vmax of a second enzyme was set to negligible levels (0.01
micromoles (Litre)_1 (min)_1). Firstly, we simulated the known synergism of inhibiting both
DHFR and DHPS, which is the most common antifolate combinatorial chemotherapy against
infectious microorganisms. The levels of dTMP when DHFR was inhibited alone reached the
lowest point (5 mM) when the Vmax for DHFR was just below 1000 micromoles (Litre)_1
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(min)_1. When DHPS was also inhibited (Vmax = 0.01 micromoles (Litre)_1 (min)_1) the
levels  of  dTMP  were  minimal  even  at  high  values  of  DHFR  Vmax  (2500  micromoles
(Litre)_1 (min)_1) (Fig. 5A). Therefore, based on this output we reasoned that the model was
suitable for the simulation of new potential combinations.
It was decided that any other possible combination should be compared against the combined 
inhibition of DHFR and DPHS as illustrated above. Explicitly, the Vmax values at which
DHFR render low levels of dTMP would be above, the same, or below the DHFR Vmax mark
of 2500 micromoles (Litre)_1 (min)_1 as witnessed when DHPS is also inhibited. 
Unexpectedly, inhibitors of the Shikimate pathway did not render a change in the Vmax for
DHFR that could be considered an improvement of the inhibition of DHFR alone. Namely, 
the inhibition of PSCVT (the targetof glyphosate) was no better than inhibiting DHFR on its
own. On the other, and rather encouragingly the inhibition of other potential targets such as 
the enzyme that modifies folates by polyglutamation (FPGS) displayed a much more
pronounced reduction in the levels of dTMP than the inhibition of DHPS (Fig. 5).
3.4 Predicting additive inhibitory effects of new combinations of antifolates
The above results prompted us to formulate a method that could facilitate a clear visualisation
of additivity on cell toxicity by new combinations of a given candidate inhibitor and an anti-
DHFR  compound.  In  experimental  pharmacology  cellular  toxicity  is  measured  as  the
concentrations of a molecule that affect cell survival: inhibitory concentrations IC50 or IC90.
The type of screening we believe is worthwhile formulating is that which detects drugs or
compounds that reduce the ICs of an anti-DHFR inhibitor at the same or lower levels than the
known synergistic combinations with anti-DHPS drugs (Fig. 5). The difference between for
instance, the IC90 of an anti-DHFR alone and in the presence of another molecule would be a
coefficient. Such a coefficient can then be used as the exponential of a natural numeric base to
render a positive scale where the point  of  no effect is one (anti-DHFR IC90 minus itself
produces an exponential zero). 
Using 2  as  the  base  this  scale  will  show maximum possible  effects  (strong additivity  or
synergy)  as  an  asymptote  that  approaches  two,  and  minimal  effects  (antagonistic)  as  an
asymptote  that  approaches  zero  (Fig.  5B).  Simply  stated  the  formula  is:  Danti-DHFR  =
2(A_B). Where  A  is the IC90 of an anti-DFHR acting alone and  B  the IC90 of such anti-
DHFR in the presence of another inhibitor at a set concentration. In this in silico model we
simulated this type of assays by running Vmax scans for DHFR while reducing the Vmax of
another  of  the  enzymes of  the  model  to  negligible  levels  (i.e. 0.01 micromoles  (Litre)_1
(min)_1). The representation of the known synergistic effect of an anti-DHFR and an anti-
DHPS is observed under this method as a change of 1.5 in the inhibitory concentrations of an
anti-DHFR (a reduction in its ICs (IC90 or IC50) of 50%) (Fig. 5B). 
When the same simulation was run with all other possible targets, significantly, inhibiting 
enzymes of the Shikimate pathway (e.g. PSCVT) did not seem to enhance the effect of 
inhibiting DHFR alone (observed as a change in the levels of dTMP). A similar trend was 
observed when lowering the Vmax values for SHMT, an enzyme directly involved in the
one-carbon transfer to folates. On the other hand, an effect well above the reference (set by 
inhibiting DHPS) was observed when reducing the levels of the Vmax for FPGS. Inhibiting
DHFR was significantly improved in the latter case with a score approaching 2. An increased 
efficacy of 100% for an anti-DHFR inhibitor when in the presence of an anti-FPGS 
compound (Fig. 5B).
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3.5 Sensitivity of the system to cell energy and redox status
A question to address in folate metabolism relates to the effect that the energy status of a cell
will  have on the biosynthesis  and usage of  folate.  As it  takes four molecules  of ATP to
produce  a  new fully  reduced  monoglutamated  folate  (every  additional  condensation  of  a
glutamate will cost an extra ATP), the full biosynthesis of folate ought to be sensitive to the
energy status of the cell. Folate biosynthesis also requires reductive equivalents in the form of
both NADH and NADPH. Recent findings from experimental work have confirmed that the
folate metabolic network has a crucial role to play in maintaining the homoeostasis of cell
biomass.47 Depending on the direction of the reactions of the folate cycle, the folate one-
carbon reactions can equally generate net  energy and reductive equivalents (i.e.  ATP and
NADPH).48,49  Consequently,  there  is  a  need  for  a  framework  that  integrates  folate
metabolism with cell growth and energy homoeostasis. In the model presented here reducing
the levels of ATP to 1% reduced the concentration of most folate metabolites (Table 2 and
Fig. 6). The reduction of other substrates such as glutamine, and NADPH had a similar effect
on the folate pool (Table 2, ESI†). However, changes to ATP and NADPH were
most significant (Fig. S5, ESI†).
We were interested in metabolites whose concentration increased under restrictive energy
conditions, as these could be feedback molecules for the folate biosynthesis and utilisation
pathways. For instance under low ATP the monoglutamated THF accumulates (Table 2 and
Fig.  6).  Importantly,  a  similar  trend  is  followed by  5-formyl-THFGlu (ffTHFGlu:  folinic
acid).  Both molecules are known to be negative regulators of folate biosynthesis enzymes
SHTM and GTPCH-I (ref. 8 and 50). Two other metabolites, SK and SAmDLp, increase to
very higher levels (Fig. S5, ESI†). A synergistic effect by SK with other carbon sources in the
promotion of cell growth has been observed in bacteria.51 However, the roles of SK, and
SAmDLp, during limited nutrient availability and low ATP are unknown. Similarly, when the
levels of NADPH decreased among the expected metabolites to become abundant, THF and
DHF  are  again  known  regulators  of  the  folate  biosynthesis.  However,  the  functions  of
DHSK,myTHFGlu, and again SAmDLp, whose concentrations are
significantly higher in low NADPH (Fig. S5, ESI†), are unknown.
4 Discussion
Folate  metabolismin  microbes  currently  suffers  from  a  paradox.  Although,  there  is  an
abundance of experimental information derived mainly from microbial models such as E. coli
and S. cerevisiae, on closer inspection there is still a lack of understanding of the regulatory
mechanisms which underpin the dynamics of folate biosynthesis and utilisation. In mammals
specific concentrations of intracellular and circulating folates are known to have predictable
implications.52  In  contrast,  we  lack  a  quantitative  framework  for  understanding  the
relationship between intrinsic folate levels and microbial cell growth and multiplication.53 A
basic initial challenge is to know the intracellular concentration of intracellular rmetabolites.
Although, there have been efforts to quantify steady state metabolite content in microbes (e.g.
E. coli),39,54 cofactors such as folates pose inherent difficulty for detection because they are
in submicromolar concentrations and mostly protein-bound. Further complications arise from
genomic driven automatic annotation of the myriad of microbial genomes. The genotypes of
folate  biosynthesis  enzymes appear  to  have local  gene variability  that  have compounding
effects  on  gene  annotation.  Nonetheless  the  architecture  of  folate  biosynthesis  pathways
seems evolutionary constrained.24,55 Consequently, the model presented here centres on the
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metabolic  reactions  that  are  widely  regarded  as  fundamental  to  a  fully  biosynthetic
microorganism and attempt to capture a broad set of parameters that allows us to integrate a
systems level overview of microbial folate metabolism.
The concentration of all folate metabolites and products represented here reach a steady state.
THFGlu and meTHFGlu represent the main forms of folate in this model under steadystate
conditions. This is a meaningful feature of the model since THFGlu is the product of the de
novo  biosynthesis of folate and meTHFGlu is the product of the condensation of the one
carbon unit (from serine or glycine) on to THFGlu. Crucially, meTHFGlu is the substrate for
the futile cycle with folinic acid (Fig.  1).56 Furthermore,  THFGlu is  a known regulatory
(inhibitor) metabolite of folate biosynthesis enzymes such as GTPCHI which catalyses the
first reaction of the pteridin biosynthesis pathway.8 It is therefore noteworthy that the model
assembled here demonstrates that these two folate intermediates, with such essential roles in
the known biochemistry of folate utilisation are the main reservoir of the folate pool. The
combined  inhibition  of  DHFR  and  DHPS  affects  the  levels  of  both  of  the  main  folate
intermediates THFGlu and meTHFGlu while the levels of methionine and dTMP do not differ
significantly  from  the  levels  observed  when  inhibiting  DHFR  alone  (Fig.  3–5).  The
combinatorial inhibition of DHFR and TS on the other hand, has drastic effects on the levels
of  dTMP  mainly  (Fig.  S3,  ESI†).  Importantly,  the  thymineless  death  is  known  as  the
mechanism mediating cell toxicity of antifolates.57 The profiles of these inhibitory trends of
folate  metabolites  and  products  fit  with  the  fact  that  anti-DHFR inhibitors  are  the  most
effective antifolate mono-therapy followed only by anti-TS compounds.5 However, it is clear
that combinatorial approaches with an anti-DHFR and a second antifolate further improve the
efficacy of anti-DHFR inhibitors to shut down folate usage reactions.58,59 Accordingly, it
was decided to explore combinations of DHFR inhibitors and a second target. Particularly,
targeting enzymes that are current candidates for antifolate chemotherapy such as SHMT and
FPGS (Fig. S4, ESI†). The best known methods for evaluating drug–drug interactions are
based  on  the  Loewe  additivity  model,  visualised  by  isobolograms  and  measured  by  the
combination index analysis.60 These empirical implementations of representing drug–drug
interactions serve the need for methods to study cell toxicity. Particularly given that usually,
evidence on the mechanisms of action and interactions of drug–drug and drugs targets is
lacking. None of these methods however, have found applicability in high-throughput (HTP)
drug screening. The need to use a range of concentrations for each of the drugs increases the
work load exponentially to levels that defeat the purpose of screening large chemical libraries.
Therefore, drug additivity is not routinely an aim in HTP drug screening. This simple method
that we decided to use here to represent antifolate combinatorial inhibition could find use in
the  search  for  chemical  hits  that  complement  synergistically  the  established  effects  of
inhibitors such as anti-DHFR drugs. Consistently, this approach shows important trends such
as  the  drastic  synergistic  effect  of  inhibiting  polyglutamation  of  folates  on  top  of  the
inhibition of DHFR. An effect that has been demonstrated experimentally in mammalian cell
lines.61 Somewhat disappointingly when we used the model to simulate the combinatorial
inhibition of other enzymes such as SHMT and enzymes involved in the Shikimate pathway,
the effects of inhibiting DHFR alone was not enhanced (Fig. 5). Nonetheless, screening large
chemical libraries is arguably a worthwhile strategy to look for drug additivity, and simple
methods such as the one presented here to measure potential synergistic interactions in HTP
projects are a necessity.
The  finding  that  folinic  acid  increases  when  the  level  of  ATP is  reduced has  important
implications  when  considered  within  the  context  of  the  regulation  of  the  metabolism  of
microbial cell growth. Folinic acid is the most chemically stable form of reduced folates that
seems to  function as  a  metabolic  sink for  the  folate  cycle.56 Folinic  acid itself  is  not  a
substrate for folate utilising enzymes, it has to be transformed back into meTHFGlu by the
ATP-driven enzyme 5-formyl THF cyclo-ligase(5-FCL: reaction (29)) before re-entering the
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folate cycle. Folinic acid has been given potential roles as a reservoir of cellular folate and as
a  regulatory  metabolite  through  the  inhibition  of  a  number  of  folate  biosynthesis
enzymes.50,56,62 As a potential folate reservoir folinic acid is present in high levels (over
70% of the folate pool) in dormant cellular forms such as plant seeds and fungi spores,56,63
and the overexpression of 5-FCL has been associated with bacterial dormant phenotypes in
liquid culture64 as well as in biofilms.65 Also, inhibiting 5-FCL has been shown to affect cell
growth.56,66 Related to the latter, 5-FCL has been described as a pathogenic factor necessary
for antifolate drug resistance in  Mycobacterium.67 Thus, folinic acid seems to be part of a
substrate cycle with invested value since it is seemingly used for both cell dormancy as well
as actively cell growth. It is possible that this ATP-driven reaction is used by the folate cycle
as  an  energy  sensor  whereby  cellular  stress  and  low ATP  is  sensed  by  the  folinic  acid
substrate loop. When conditions are more favourable, activation of folinic acid restores the
flux  downstream  this  futile  cycle.  Sensitivity  in  metabolic  regulation  is  the  relationship
between the relative change in enzyme activity and the relative change in concentration of a
regulator.68 As an outlining feature this model of the folate biosynthesis pathway and the
folate  cycle  substantiates  the  cited  works  that  propose  the  5-FCL reaction  as  a  potential
substrate cycle as part of the regulatory signals of the folate metabolism.
A kinetic model to detect parameter dependencies can have limitations. The model outputs are
influenced by the accuracy of the enzymatic kinetic parameters. However, these parameters
have inherent variability due to differences in the experimental conditions in which they were
quantified.  Particularly,  when  as  in  this  model,  the  objective  was  to  build  a  generic
construction of the relevant microbial pathways. We have mitigated against this limitation by
compiling a metabolic network of consensus reactions for folate biosynthesis across species,
and  the  distributions  for  a  large  number  of  values  for  the  relevant  kinetic  from generic
databases as well as the literature. Additionally, the model is well informed by the inclusion
of  the  initial  steady  state  concentrations  for  the  majority  of  metabolites  from studies  on
microbial  model  organisms  which  report  absolute  values  using  modern  metabolomics
techniques. The robustness and accuracy of this type of model then becomes apparent, as is
the case in this work, by the steady-state values of metabolic products that agree with the
literature data and the predictability of the effects of local parameter variations. The latter
includes the agreement of the model with the known effects of existing inhibitors.
5 Conclusions
We have assembled a generic mathematical model of microbial folate biosynthesis and usage.
This model is able to reproduce many of the key biochemical dynamics which underpin folate
metabolism in microorganisms. We acknowledge that the model has limitations. For instance,
model  outputs  are  inexorably dictated by enzymatic kinetic parameters.  These parameters
have inherent variability due to differences in the experimental conditions in which they were
quantified. Equally relevant to the validity of the model is that its foundations are based on
the  general  consensus  within  the  field  that  these  are  the  accepted  reactions  of  folate
biosynthesis and utilisation. For example, for some reactions such as the initial steps of the
pterin biosynthesis pathway alternative catalytic steps have been proposed.69Nonetheless, the
model is consistent with the biology of folate metabolism and provides a number of useful
biochemical insights as well as results which have meaningful implications. These include the
presentation of two folate intermediates of the folate cycle, THFGlu and meTHFGlu, as the
main components of  the  network of  folate  substrates.  The simulation of the inhibition of
certain  folate  enzymes  seems  to  us  particularly  useful.  DHFR  stands  out  as  the  most
efficacious target to inhibit and any combinatorial approach should consider including an anti-
DHFR.  A combination that  results  with effects stronger than the benchmark of inhibiting
DHPS and DHFR seems to e the inhibition of the polyglutamation (FPGS) of folates together
with  inhibiting  DHFR.  These  findings  could  be  pertinent  for  the  future  development  of
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antifolates.  Lastly,  and  of  significant  interest  this  model  supports  that  the  folinic  acid
biosynthesis loop appears to act as a folate-mediated regulatory circuit in cell growth. In the
future we hope to use this model to explore this finding in greater depth.
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